Tumours, which lose MHC expression or acquire upstream defects in antigen presentation, will be relatively resistant to immune‐mediated elimination by tumour‐specific T‐cells, resulting in impaired activation of CD4+ (MHC‐II recognition) and CD8+ T‐cells (MHC‐I recognition). The gene discussed is CD8A; the disease is neoplasm.